

NSW Cancer Research Education

Molecular Tumour Board:
Melanoma Institute Australia
Personalised Immunotherapy Program

Statewide Seminar Series 2023
Tuesday 17 October, 12.30 - 1.30 pm



**A/Professor
James Wilmott**

Senior Scientist



Dr Jorja Braden

Medical Oncologist &
PhD candidate





Dr Francesca Watts

Pathology Fellow



Dr Tuba Gide

Postdoctoral Fellow

17th |  **12:30 – 1:30** |  **Online Webinar**
2023 PM PM

REGISTER NOW

The Research Capacity Building Grants are supported by Cancer Institute NSW



Session Information

Join us for this educational Molecular Tumour Board session with presenters from the Melanoma Institute Australia giving insight to their Personalised Immunotherapy Program.

This session will cover:

- The background around genomic, transcriptomic and tumour immune profiling as biomarkers of response to immunotherapies.
- Biomarker multidisciplinary discussion of somatic, transcriptomic and immune profiling of two patients enrolled in the program.
- Topics covered will include tumour mutation burden, gene expression signatures, quantitative pathology and immunohistochemistry for novel checkpoint ligands.

Speakers



Associate Professor James Wilmott is the senior scientist at the Melanoma Institute Australia's, Translational Research laboratory at The University of Sydney. He works with clinical teams and patients to identify areas of need, discover solutions and work collaboratively to implement these findings into clinical workflows with a focus on the integration of clinicopathology, genomics, gene expression, and high-dimensional spatial pathology to develop tools that improve treatment selection and aid in the understanding of drug resistance. James leads the Personalised Immunotherapy Program (PIP), which aims to revolutionise the way immunotherapies are used in clinical trials and how treatments are selected for each patient in routine clinical care.



Dr Jorja Braden is a medical oncologist and PhD candidate in the Melanoma Translational Research Group at the University of Sydney. Dr Braden's PhD focuses on the sequencing of targeted therapy and immunotherapy in melanoma. She is the recipient of a PhD Scholarship from Sydney Cancer Partners with funding from Cancer Institute NSW and The Ben Garrow PhD Scholarship through the Melanoma Institute Australia.



Dr Francesca Watts is a pathology fellow with the Melanoma Institute Australia. She completed her training in anatomical pathology at the Royal Prince Alfred Hospital, Sydney and gained fellowship of the Royal College of Pathologists of Australasia in 2022.



Dr Tuba Gide is a post-doctoral researcher at the Melanoma Institute Australia, The University of Sydney, and recipient of a Cancer Institute NSW Early Career Fellowship in 2021. Dr Gide completed her PhD in 2019, focusing on the identification of biomarkers of response and resistance to anti-PD-1 based immunotherapies in metastatic melanoma. Her current research focuses on integrating cutting-edge technologies to identify the patients who will benefit from the standard-of-care immunotherapies and the patients who require treatment with novel drug combinations, ultimately enabling more accurate patient stratification into personalised treatments and improving patients' outcomes.